Gujarat Themis Biosyn Ltd. (GUJTHEM): Gujarat Themis Biosyn Share Price Rises 5.10% on Intraday Move
- September 7, 2026
- Posted by: Harsh Piplani
- Category: News
Gujarat Themis Biosyn Share Price is trading at Rs 432.75, up 5.10% from the previous close of Rs 411.75, with market capitalisation at Rs 5,359 Cr as of 07 September 2026 at 10:23:22 AM IST. The move makes GUJTHEM one of the stocks in news today, even though the latest Univest data confirms the price event without establishing a company-specific catalyst. For investors tracking Gujarat Themis Biosyn Share Price Today, the key context is a higher valuation profile in the healthcare space, along with ratios that place the company well above the broader industry median on earnings multiples. Univest readers can use this stock news update to understand whether the share price rise is being supported by business fundamentals and where it sits versus peers in Pharmaceuticals & Drugs.
Gujarat Themis Biosyn Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 432.75 |
| Previous Close | Rs 411.75 |
| Today's Move | Rs 21 (+5.1%) |
| Open | Rs 411.8 |
| High | Rs 441.85 |
| Low | Rs 409.8 |
| Turnover | Rs 0.93 crore |
| Market Capitalisation | Rs 5,359 crore |
| Market Cap Category | Mid Cap |
Gujarat Themis Biosyn Ltd. (GUJTHEM) rose to Rs 432.75 from the previous close of Rs 411.75, a move of Rs 21 or 5.1%. The stock opened at Rs 411.8, reached a high of Rs 441.85, recorded a low of Rs 409.8.
Gujarat Themis Biosyn Share Price moved from Rs 411.75 to Rs 432.75, a gain of Rs 21 on the day. The stock opened at Rs 411.8, touched a high of Rs 441.85 and a low of Rs 409.8, showing that the price rise has taken place within a fairly active intraday range. Turnover stood at Rs 0.93 Cr, which adds market colour to the move but does not by itself explain the trigger. For readers scanning Gujarat Themis Biosyn Share Price Live, the latest Univest figures confirm the stock was trading higher in morning trade, but the data does not establish a separate news catalyst. That is why the share price update is best read as a verified price action event rather than a story built around a claimed reason.
Gujarat Themis Biosyn Ltd. (GUJTHEM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 5,359 crore |
| P/E Ratio | 110.07x |
| P/B Ratio | 5.11x |
| ROE | 21.69% |
| ROCE | 27.48% |
| EPS | Rs 3.74 |
| Book Value Per Share | Rs 80.59 |
| Dividend Yield | 0.16% |
Gujarat Themis Biosyn Ltd. (GUJTHEM) fundamental metrics show P/E 110.07x, P/B 5.11x, ROE 21.69%, ROCE 27.48%. These figures provide context only and are not a buy or sell signal.
Gujarat Themis Biosyn Ltd. has a market capitalisation of Rs 5359 crore and falls in the Mid Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 110.07x, P/B at 5.11x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 21.69% and ROCE of 27.48%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 3.74, book value per share of Rs 80.59, dividend yield of 0.16%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 32.83x, median ROE of 11.78%, median ROCE of 13.65%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 110.07x |
| Benchmark Median P/E | 32.83x |
| Benchmark Average P/E | 48.79x |
| Benchmark P/E Range | 3.2x to 659.73x |
| Company P/B Ratio | 5.11x |
| Benchmark Median P/B | 2.92x |
| Company ROE | 21.69% |
| Benchmark Median ROE | 11.78% |
| Company ROCE | 27.48% |
| Benchmark Median ROCE | 13.65% |
| Company Market Capitalisation | Rs 5,359 crore |
| Benchmark Median Market Cap | Rs 674.09 crore |
Gujarat Themis Biosyn Ltd. (GUJTHEM) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Gujarat Themis Biosyn Ltd. (GUJTHEM) has a P/E ratio of 110.07x, which is above the benchmark median of 32.83x, a difference of +235.27%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Gujarat Themis Biosyn Ltd. (GUJTHEM) has a ROE of 21.69%, which is above the benchmark median of 11.78%, a difference of +84.13%. Gujarat Themis Biosyn Ltd. (GUJTHEM) has a ROCE of 27.48%, which is above the benchmark median of 13.65%, a difference of +101.32%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,55,633.71 | 37.67 | 5.27 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,41,576.41 | 82.59 | 13.68 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,84,478.41 | 84.58 | 20.55 | 26.76 | 19.27 |
| Cipla Ltd. | CIPLA | 1,11,888.39 | 33.19 | 3.18 | 11.83 | 16 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,11,820.18 | 24.78 | 4.15 | 19.69 | 21.39 |
Gujarat Themis Biosyn Ltd. (GUJTHEM) has a P/E ratio of 110.07x compared with the displayed peer median of 37.67x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 21.69% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 27.48% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Gujarat Themis Biosyn Ltd. (GUJTHEM) has a market capitalisation of Rs 5,359 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching Gujarat Themis Biosyn
- The share price is up 5.10% today, making Gujarat Themis Biosyn Share Price one of the notable movements in Stocks in News.
- The stock is trading at Rs 432.75 versus a previous close of Rs 411.75, so the latest price action is clearly positive.
- The P/E of 110.07 and P/B of 5.11 place the company at a richer valuation than the industry median.
- ROE of 21.69 and ROCE of 27.48 show stronger profitability ratios than the same-industry benchmark medians.
- In healthcare, valuation often matters as much as growth; Univest users can track how this stock compares with larger pharma names.
About Gujarat Themis Biosyn
Gujarat Themis Biosyn Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company is followed on both NSE and BSE under the symbol GUJTHEM. Based on the latest Univest data, the market is treating it as a mid-sized listed pharma name with a Rs 5,359 Cr market cap and earnings metrics that support a premium relative to many industry names. The business context matters because pharmaceutical stocks are often judged on a mix of profitability, scale, and the consistency of financial results. For readers searching Gujarat Themis Biosyn Latest News or Gujarat Themis Biosyn Company News, the main point is straightforward: the stock’s share price movement should be viewed together with valuation and sector positioning, not in isolation. Univest keeps the company within its broader stock coverage so investors can follow the share price update alongside company-level market information.
Frequently Asked Questions
Why is Gujarat Themis Biosyn Share Price rising today?
Ans. Gujarat Themis Biosyn Share Price is up 5.10% and trading at Rs 432.75. The latest Univest figures confirm the price move, but they do not establish a company-specific catalyst for the rise.
What is Gujarat Themis Biosyn Share Price Today?
Ans. Gujarat Themis Biosyn Share Price Today is Rs 432.75, compared with the previous close of Rs 411.75. The stock is trading higher in morning market action and remains in focus on Univest.
What is the market cap of Gujarat Themis Biosyn?
Ans. Gujarat Themis Biosyn has a market capitalisation of Rs 5,359 Cr. That places it above the same-industry median in the healthcare benchmark set and gives context to the current share price move.
How does Gujarat Themis Biosyn compare on valuation?
Ans. Gujarat Themis Biosyn trades at a P/E of 110.07 and a P/B of 5.11. Both are above the same-industry medians, indicating a richer valuation than much of the pharmaceuticals universe.
What do ROE and ROCE show for Gujarat Themis Biosyn?
Ans. ROE is 21.69 and ROCE is 27.48. Both are above the benchmark medians in the same industry, suggesting stronger return ratios than many listed healthcare peers. The relevant peer median ROE is 11.78%.
What are the EPS and book value for Gujarat Themis Biosyn?
Ans. EPS is Rs 3.74 and book value is Rs 80.59. EPS reflects earnings attributable to each share, while book value shows the accounting net worth per share behind the stock.
How does Gujarat Themis Biosyn compare with pharma peers?
Ans. Gujarat Themis Biosyn is smaller than Sun Pharma, Divi’s Laboratories, Torrent Pharmaceuticals, Cipla and Zydus Lifesciences on market cap, but its P/E is higher than all five peers listed here.
What should investors monitor in Gujarat Themis Biosyn Stock News?
Ans. Investors can watch price action, turnover, valuation ratios and sector positioning. Univest also helps track Gujarat Themis Biosyn Share Price Live, financials, 52-week levels and broader market updates.
Track Gujarat Themis Biosyn Share Price on Univest
Use Gujarat Themis Biosyn Ltd. (GUJTHEM) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
If you are following Gujarat Themis Biosyn Share Price, Univest can help you monitor live share price movement, key valuation ratios, market cap, 52-week levels, company financials, sector comparison and broader market insights in one place. It is a practical way to track Gujarat Themis Biosyn Share Price Today alongside related stock news and fundamental context.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
